Emergent BioSolutions submits development plan for anthrax vaccine

ROCKVILLE, Md -- Emergent BioSolutions Inc. has submitted a development plan to the FDA for its Recombinant Protective Antigen (rPA) anthrax vaccine candidate. Emergent submitted the plan in response to the Department of Health and Human Services’ amendment to its request for proposal to develop and deliver up to 25 million doses of an rPA vaccine for the Strategic National Stockpile.

“We are pleased to successfully meet this HHS requirement ahead of schedule and look forward to receiving comments and guidance from the FDA,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “As the premier supplier of medical countermeasures to the U.S. government, we are fully committed to moving our rPA program forward and remain optimistic of our competitiveness to receive any award granted by HHS to develop and supply the Strategic National Stockpile with an rPA vaccine.”